Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression

Open access
Williamson, David J., Gogate, Jagadish P., Sliwa, Jennifer K. Kern, Manera, Lewis S., Preskorn, Sheldon H., Winokur, Andrew, Starr, H. Lynn, Daly, Ella J. · 2022 · The Journal of Clinical Psychiatry

Abstract

To describe the tolerability of esketamine nasal spray based on the adverse event profile observed during treatment sessions occurring early and later over the course of treatment. ) and nonresponse to ≥ 2 oral antidepressants received esketamine nasal spray (56 or 84 mg) twice weekly during a 4-week induction phase, weekly for weeks 5-8, and weekly or every 2 weeks thereafter as maintenance treatment, in conjunction with a new oral antidepressant. A post hoc analysis using descriptive statistics evaluated occurrence (incidence, frequency, severity) and recurrence (incidence and severity) of events of specific interest. In patients treated with esketamine nasal spray plus a newly initiated oral antidepressant (n = 928), spontaneously reported adverse events of dizziness, nausea, sedation, vertigo, and increased blood pressure were more likely to recur after the first week of treatment if they occurred more frequently (twice > once > none) during the first week. The same pattern was observed when these events were assessed by structured instruments. Incidences of dizziness, dissociation, increased blood pressure, nausea, vertigo, and sedation were highest in week 1 of treatment (20.6%, 16.7%, 4.3%, 14.0%, 12.1%, and 3.8%, respectively) and decreased thereafter. Initial occurrences and subsequent recurrences of events were mostly mild or moderate in severity. Adverse events during treatment with esketamine nasal spray plus an oral antidepressant generally become less frequent with ongoing treatment, and the majority are mild or moderate in severity. ClinicalTrials.gov identifiers: NCT02493868; NCT02497287.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.21m14318

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 16

Metadata

Authors
Williamson, D. J., Gogate, J. P., Sliwa, J. K. K., Manera, L. S., Preskorn, S. H., Winokur, A., Starr, H. L., & Daly, E. J.
Affiliations
  • Janssen Scientific Affairs (United States) (US)
  • Janssen Research & Development (United States) (US)
  • University of Kansas (US)
  • UConn Health (US)
Corresponding author
Williamson, David J.
Venue
The Journal of Clinical Psychiatry
Published
2022-09-19
Volume
83
Issue
6
ISSN
  • 0160-6689 (ISSN-L)
  • 1555-2101
OpenAlex
W4296281078
Cited by
15
References
7
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 4 · 2022: 1
FWCI
1.80
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
Janssen Scientific Affairs
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords
esketamine nasal spray, adverse events, tolerability, dizziness, vertigo, nausea, sedation, dissociation, blood pressure, antidepressant non-response, treatment-emergent adverse events
MeSH terms
Antidepressive Agents, Depression, Depressive Disorder, Major, Major Depressive Disorder, Dizziness, Humans, Ketamine, Nausea, Vertigo, Clinical Trials, Phase III as Topic, Nasal Sprays, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression. https://app.cochat.ai/papers/10.4088/jcp.21m14318
The paper
Williamson, D. J., Gogate, J. P., Sliwa, J. K. K., Manera, L. S., Preskorn, S. H., Winokur, A., Starr, H. L., & Daly, E. J. (2022). Longitudinal Course of Adverse Events With Esketamine Nasal Spray: A Post Hoc Analysis of Pooled Data From Phase 3 Trials in Patients With Treatment-Resistant Depression. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.21m14318

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.